Fundraising FoxSkinJect
Pittsburgh, US · Founded 2015 · Pennsylvania corporation
Find your way into SkinJect
Sign up to see every warm intro you have to SkinJect
- Paths you didn't know you had: your email and LinkedIn already hold routes to the SkinJect team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
SkinJect develops a dissolvable microneedle patch delivery system to treat non-melanoma skin cancers such as basal cell carcinoma by stimulating an immune response against the disease. The device combines FDA-approved microneedles and chemotherapy cargo for topical skin cancer treatment.
Founders & leadership
JN
James NolanExecutive
JD
Joseph DonnellyExecutive
Board
AF
Anthony FlorenceBoard director
MF
Michael FareBoard director
KM
Kenneth MelaniBoard director
JP
James P. QuinlanChairman
CB
Carolyn BonnerBoard director
EJ
Edward J. BrennanBoard director
Reported raises · per SEC filings
Form D private placements$3.9M disclosed across 3 of 4 rounds · 2015–2021
▶$895.1KraisedJul 2021 · 11 investors · BiotechnologyRule 506(b)
▶$895.1KraisedJul 2021 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joseph DonnellyExecutive Officer, Director
- James NolanDirector
- Michael FareExecutive Officer, Director
- Kenneth MelaniExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $895.1K
- First sale
- Jul 2021
- Incorporated
- Corporation, Pennsylvania
- Federal exemptions
- 06b
▶$2.5MraisedMay 2019 · 13 investors · BiotechnologyRule 506(b)
▶$2.5MraisedMay 2019 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kenneth MelaniDirector
- James NolanExecutive Officer, Director
- Joseph DonnellyExecutive Officer, Director
- Anthony FlorenceDirector, Promoter
- Michael FareExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- First sale
- May 2019
- Incorporated
- Corporation, Pennsylvania, 2015
- Federal exemptions
- 06b
▶$4.4MofferedMar 2017 · BiotechnologyRule 506(b)
▶$4.4MofferedMar 2017 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James NolanExecutive Officer, Director
- Kenneth MelaniDirector
- Anthony FlorenceDirector, Promoter
- Joseph DonnellyExecutive Officer, Director
- Michael FareDirector
- Offering amount
- $4.4M
- Incorporated
- Corporation, Pennsylvania, 2015
- Federal exemptions
- 06b
▶$500KraisedDec 2015 · 8 investors · BiotechnologyRule 506(b)
▶$500KraisedDec 2015 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anthony FlorenceDirector, Promoter
- Michael FareDirector
- James NolanExecutive Officer, Director
- Kenneth MelaniDirector
- Joseph DonnellyExecutive Officer, Director
- Offering amount
- $1.3M
- Amount sold
- $500K
- Minimum investment
- $50K
- First sale
- May 2015
- Incorporated
- Corporation, Pennsylvania, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
American Cancer Society (ACS)The American Cancer Society is a nonprofit organization that provides cancer research updates, screening and prevention guidance, and community engagement opportunities. It serves individuals seeking cancer information and those who want to support cancer research and patient advocacy efforts.
OsfhealthcareOSF HealthCare is an integrated health system operating 16 hospitals, urgent care clinics, primary and specialty care facilities, and digital health services across Illinois and Michigan. The organization serves patients through inpatient care, outpatient clinics, home health services, and virtual care platforms.
CancerresearchukCancer Research UK funds research across discovery, detection, prevention and treatment of cancer to improve patient outcomes and extend survival. It operates as a research funder and scientific organization serving academic and clinical researchers.
MD Anderson Cancer CenterUT MD Anderson is a cancer research and treatment center that provides patient care, conducts research, and offers education in cancer prevention and treatment. It is part of the University of Texas System and operates as a nonprofit medical institution.
Companies working in the same space as SkinJect.
Frequently asked questions
- What does SkinJect do?
- SkinJect develops a dissolvable microneedle patch delivery system to treat non-melanoma skin cancers such as basal cell carcinoma by stimulating an immune response against the disease. The device combines FDA-approved microneedles and chemotherapy cargo for topical skin cancer treatment.
- How much funding has SkinJect raised?
- SkinJect has disclosed $3.9M raised across 3 of its 4 known rounds.
- Where is SkinJect headquartered?
- SkinJect is headquartered in Pittsburgh, US.